4.4 Article

Attributable Inpatient Costs of Recurrent Clostridium difficile Infections

期刊

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
卷 35, 期 11, 页码 1400-1407

出版社

CAMBRIDGE UNIV PRESS
DOI: 10.1086/678428

关键词

-

资金

  1. Cubist Pharmaceuticals, Lexington, Massachusetts
  2. Sanofi Pasteur
  3. Merck
  4. Pfizer

向作者/读者索取更多资源

OBJECTIVE. To determine the attributable inpatient costs of recurrent Clostridium difficile infections (CDIs). DESIGN. Retrospective cohort study. SETTING. Academic, urban, tertiary care hospital. PATIENTS. A total of 3,958 patients aged 18 years or more who developed an initial CDI episode from 2003 through 2009. METHODS. Data were collected electronically from hospital administrative databases and were supplemented with chart review. Patients with an index CDI episode during the study period were followed up for 180 days from the end of their index hospitalization or the end of their index CDI antibiotic treatment (whichever occurred later). Total hospital costs during the outcome period for patients with recurrent versus a single episode of CDI were analyzed using zero-inflated lognormal models. RESULTS. There were 421 persons with recurrent CDI (recurrence rate, 10.6%). Recurrent CDI case patients were significantly more likely than persons without recurrence to have any hospital costs during the outcome period (P < .001). The estimated attributable cost of recurrent CDI was $ 11,631 (95% confidence interval, $ 8,937-$ 14,588). CONCLUSIONS. The attributable costs of recurrent CDI are considerable. Patients with recurrent CDI are significantly more likely to have inpatient hospital costs than patients who do not develop recurrences. Better strategies to predict and prevent CDI recurrences are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据